Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2017-04-09 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于公开发行可转换公司债券摊薄即期回报及填补措施的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company regarding the public issuance of convertible bonds, including the impact on immediate returns, financial assumptions, risk warnings, necessity and rationality of the issuance, and measures to mitigate dilution effects. It includes financial data projections, regulatory references (China Securities Regulatory Commission), and corporate governance commitments. The document is not a full annual or interim report but a specific update on capital raising and its financial impact. It is not a simple announcement of a report publication but a substantive disclosure about financing activities and related financial effects. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2017-04-09 Chinese
关于终止2016年非公开发行股票事项的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the termination of a previously planned non-public issuance of shares. It details the board meetings and shareholder meetings that approved the initial plan, the reasons for termination, and the company's future financing plans. The document does not contain financial statements or detailed financial data but is a formal notice about a capital raising activity being stopped and future plans for convertible bonds. This fits the category of a Capital/Financing Update (CAP) as it relates to changes in the company's financing activities and capital structure.
2017-04-09 Chinese
关于公司前次募集资金使用情况的鉴证报告
Regulatory Filings
2017-04-09 Chinese
关于第三届监事会第十一次会议决议的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 11th meeting of the third Supervisory Board of 特一药业集团股份有限公司. The content focuses on the approval of a convertible bond issuance plan, including terms of the bond, issuance scale, pricing, conversion terms, redemption and repurchase clauses, bondholder meeting rules, guarantees, and use of proceeds. It also includes voting results and mentions that these resolutions will be submitted to the shareholders' meeting for approval. The document is not a financial report or earnings release but rather a formal announcement of decisions related to capital raising and financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed substantive content, not just a brief announcement or notice, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2017-04-09 Chinese
关于公开发行可转换公司债券募集资金运用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "Feasibility Analysis Report on the Use of Funds Raised from the Public Issuance of Convertible Corporate Bonds" by a pharmaceutical company. It details the investment plans, project backgrounds, construction and equipment details, and economic benefits related to the use of funds raised from convertible bonds issuance. The content is focused on the feasibility and planned use of capital raised through a financing activity (convertible bonds issuance). There is no indication that this is an annual report, audit report, earnings release, or other financial statement. Instead, it is a detailed analysis related to capital raising and the intended use of those funds. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed project and investment information, supporting a high confidence in classification.
2017-04-09 Chinese
关于第三届董事会第十三次会议决议的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th meeting of the third board of directors of 特一药业集团股份有限公司. It includes extensive information about the proposed issuance of convertible bonds, including terms, conditions, voting results, and plans for a subsequent shareholders meeting to approve these proposals. The document is not a full financial report but rather a formal announcement of board decisions related to capital raising and financing activities. It does not contain financial statements or quarterly results but focuses on the approval and details of a convertible bond issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2017-04-09 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.